CN110051702A - A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza - Google Patents
A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza Download PDFInfo
- Publication number
- CN110051702A CN110051702A CN201910491110.5A CN201910491110A CN110051702A CN 110051702 A CN110051702 A CN 110051702A CN 201910491110 A CN201910491110 A CN 201910491110A CN 110051702 A CN110051702 A CN 110051702A
- Authority
- CN
- China
- Prior art keywords
- foot
- influenza
- mouth disease
- hand
- probiotic formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 55
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 55
- 206010022000 influenza Diseases 0.000 title claims abstract description 43
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 40
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 title claims abstract description 35
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 title claims abstract description 35
- 238000009472 formulation Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000002265 prevention Effects 0.000 claims abstract description 21
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 3
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 6
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of probiotic formulation more particularly to the probiotic formulations of a kind of prevention and treatment hand-foot-and-mouth disease, influenza.Probiotic formulation of the invention contains in every 0.05 milliliter of probiotic formulation solution: animal bifidobacteria Bb-12:1.5~2.0 hundred million；Lactobacillus acidophilus: 1.5~2.0 hundred million；Lactobacillus rhamnosus: 1.5~2.0 hundred million；Lactobacillus reuteri: 0~2.0 hundred million.Probiotic combinations of the invention can symbiotic co-existence, can induce body generate non-specific antibody, improve Abwehrkraft des Koepers；And can induce body generation and specific antibody is generated to the main pathogens of hand-foot-and-mouth disease and influenza, there is certain preventive and therapeutic effect to hand-foot-and-mouth disease and influenza.
Description
Technical field
The present invention relates to a kind of probiotic formulation more particularly to the probiotic formulations of a kind of prevention and treatment hand-foot-and-mouth disease, influenza.
Background technique
Probiotics refers to the balance that can improve host's enteral Tiny ecosystem, and has the active microorganism of positive benefit to host.Benefit
The digestion and absorption of the raw helpful nutriment of bacterium；Generate important nutriment；The infection of bacterial virus is resisted, is promoted immune
Power can remove harmful bacteria to functions such as the injuries of body.
It, can not since probiotics currently on the market only non-specifically improves Abwehrkraft des Koepers to a certain extent
Specific antibody is generated for the main pathogens of hand-foot-and-mouth disease and influenza, therefore there is no too obvious to the prevention and treatment of these diseases
Influence.
The present invention specializes in and selects the main pathogens generation spy that can induce body generation to hand-foot-and-mouth disease and influenza
The probiotics of heterogenetic antibody is combined, and guarantees that symbiosis can coexists in these probiotics.
Summary of the invention
(1) technical problems to be solved
The present invention is non-specifically to improve body to a certain extent to support to overcome probiotics currently on the market
Drag, the shortcomings that specific antibody can not being generated for the main pathogens of hand-foot-and-mouth disease and influenza, the invention solves
Technical problem is to provide a kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza.
(2) technical solution
In order to solve the above-mentioned technical problems, the present invention provides such a prevention and treatment hand-foot-and-mouth diseases, the benefit of influenza
Raw bacterium is formulated, and contains in every 0.05 milliliter of probiotic formulation solution:
Animal bifidobacteria Bb-12:1.5~2.0 hundred million；
Lactobacillus acidophilus: 1.5~2.0 hundred million；
Lactobacillus rhamnosus: 1.5~2.0 hundred million；
Lactobacillus reuteri: 0~2.0 hundred million.
Preferably, contain in every 0.05 milliliter of probiotic formulation solution:
Preferably, contain in every 0.05 milliliter of probiotic formulation solution:
Preferably, contain in every 0.05 milliliter of probiotic formulation solution:
Above-mentioned probiotics of the invention is to select to be proved to be to have from selecting in the probiotics of 500-1000 kind in enteron aisle
It beneficial to the probiotics of human life and health, and selects to prevent and treat helpful probiotics to influenza or hand-foot-and-mouth disease, select simultaneously
The above-mentioned probiotics selected being capable of symbiotic co-existence.
The indication of probiotic formulation of the invention has:
Before≤3 years old intestinal flora systems " adult "；
After 65 years old rear intestinal flora significant changes；
Chronic diarrhea person；
Take antibiotic person for a long time；
Eczema, allergy etc..
The 1-2 months probiotic combinations for starting to take prevention and treatment influenza before Influenza flu season, take 1 drop daily, and a drop is
It 0.05 milliliter, continuously takes 2-3 weeks.
The 1-2 months probiotic combinations for starting to take prevention and treatment hand-foot-and-mouth disease, take 1 drop daily before hand-foot-and-mouth disease season,
One drop i.e. 0.05 milliliter, continuously takes 3-5 weeks.
(3) beneficial effect
Symbiosis can coexists in probiotic combinations of the invention, and induction body improves non-specific antibody, improve body and resist
Power.
It induces body generation and specific antibody is generated to the main pathogens of hand-foot-and-mouth disease and influenza, to hand-foot-and-mouth disease and stream
Sense has certain preventive and therapeutic effect.
Specific embodiment
Embodiment 1
The probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, contains in every 0.05 milliliter of probiotic formulation solution:
Influenza (swin flu, second stream) is prevented and treated with above-mentioned formula.
Embodiment 2
The probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, contains in every 0.05 milliliter of probiotic formulation solution:
With above-mentioned formula prevention and treatment influenza (swin flu, second stream) and hand-foot-and-mouth disease.
Embodiment 3
The probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, contains in every 0.05 milliliter of probiotic formulation solution:
With above-mentioned formula prevention and treatment influenza (swin flu, second stream) and hand-foot-and-mouth disease.
Embodiment 4
The probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, contains in every 0.05 milliliter of probiotic formulation solution:
With above-mentioned formula prevention and treatment influenza (swin flu, second stream) and hand-foot-and-mouth disease.
Embodiment 5
The probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, contains in every 0.05 milliliter of probiotic formulation solution:
With above-mentioned formula prevention and treatment influenza (swin flu, second stream) and hand-foot-and-mouth disease.
Above-mentioned probiotics of the invention is to select to be proved to be to have from selecting in the probiotics of 500-1000 kind in enteron aisle
It beneficial to the probiotics of human life and health, and selects to prevent and treat helpful probiotics to influenza or hand-foot-and-mouth disease, select simultaneously
The above-mentioned probiotics selected being capable of symbiotic co-existence.
The indication of probiotic formulation of the invention has:
Before≤3 years old intestinal flora systems " adult "；
After 65 years old rear intestinal flora significant changes；
Influenza (swin flu, second stream)；
Hand-foot-and-mouth disease；
Chronic diarrhea person；
Take antibiotic person for a long time；
Eczema, allergy etc..
The 1-2 months probiotic combinations for starting to take prevention and treatment influenza before Influenza flu season, take 1 drop daily, and a drop is
It 0.05 milliliter, continuously takes 2-3 weeks.
The 1-2 months probiotic combinations for starting to take prevention and treatment hand-foot-and-mouth disease, take 1 drop daily before hand-foot-and-mouth disease season,
One drop i.e. 0.05 milliliter, continuously takes 3-5 weeks.
Symbiosis can coexists in probiotic combinations of the invention, and body is helped to improve non-specific antibody, improve body and resist
Power.It induces body generation and specific antibody is generated to the main pathogens of hand-foot-and-mouth disease and influenza, have to hand-foot-and-mouth disease and influenza
Certain preventive and therapeutic effect.
The preferred embodiment of the present invention above described embodiment only expresses, the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, several deformations can also be made, improves and substitutes, these belong to this hair
Bright protection scope.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (4)
1. the probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease, influenza, which is characterized in that every 0.05 milliliter of probiotic formulation solution
In contain:
Animal bifidobacteria Bb-12:1.5~2.0 hundred million；
Lactobacillus acidophilus: 1.5~2.0 hundred million；
Lactobacillus rhamnosus: 1.5~2.0 hundred million；
Lactobacillus reuteri: 0~2.0 hundred million.
2. the probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease according to claim 1, influenza, which is characterized in that every 0.05
Contain in the probiotic formulation solution of milliliter:
3. the probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease according to claim 1, influenza, which is characterized in that every 0.05
Contain in the probiotic formulation solution of milliliter:
4. the probiotic formulation of a kind of prevention and treatment hand-foot-and-mouth disease according to claim 1, influenza, which is characterized in that every 0.05
Contain in the probiotic formulation solution of milliliter:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910491110.5A CN110051702A (en) | 2019-06-06 | 2019-06-06 | A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910491110.5A CN110051702A (en) | 2019-06-06 | 2019-06-06 | A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110051702A true CN110051702A (en) | 2019-07-26 |
Family
ID=67325646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910491110.5A Pending CN110051702A (en) | 2019-06-06 | 2019-06-06 | A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110051702A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Compositions based on probiotics and their use in the prevention and/or treatment of respiratory lesions and/or infections and in the improvement of intestinal function |
| CN101336938A (en) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
-
2019
- 2019-06-06 CN CN201910491110.5A patent/CN110051702A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Compositions based on probiotics and their use in the prevention and/or treatment of respiratory lesions and/or infections and in the improvement of intestinal function |
| CN101336938A (en) * | 2007-07-02 | 2009-01-07 | 青岛东海药业有限公司 | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease |
Non-Patent Citations (3)
| Title |
|---|
| GAREAU MG等: "Probiotics and the gut microbiota in intestinal health and disease", 《NAT REV GASTROENTEROL HEPATOL》 * |
| 尹斐弘等: "儿童重症手足口病肠道菌群和肠道黏膜通透性的研究进展", 《中国微生态学杂志》 * |
| 邹杨等: "益生菌防治呼吸道感染的研究进展", 《中国当代医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Effects of Bacillus subtilis KN-42 on growth performance, diarrhea and faecal bacterial flora of weaned piglets | |
| Geng et al. | Probiotics Lactobacillus rhamnosus GG ATCC53103 and Lactobacillus plantarum JL01 induce cytokine alterations by the production of TCDA, DHA, and succinic and palmitic acids, and enhance immunity of weaned piglets | |
| Rad | Can probiotics prevent or improve common cold and influenza? | |
| Chang et al. | Fructo-oligosaccharide alleviates soybean-induced anaphylaxis in piglets by modulating gut microbes | |
| SG190215A1 (en) | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections | |
| CN102917714A (en) | Growing up milks containing probiotic micro-organisms | |
| Li et al. | In-vitro digestion by simulated gastrointestinal juices of Lactobacillus rhamnosus cultured with mulberry oligosaccharides and subsequent fermentation with human fecal inocula | |
| Quilodrán-Vega et al. | Isolation of lactic acid bacteria from swine milk and characterization of potential probiotic strains with antagonistic effects against swine-associated gastrointestinal pathogens | |
| Rostami et al. | Efficacy of probiotics in prevention and treatment of infectious diseases | |
| Loo et al. | A current overview of next-generation probiotics and their prospects in health and disease management | |
| SG190216A1 (en) | Non-replicating probiotic bacteria and prevention or treatment of infections to reduce absence from school or daycare | |
| Nagaraj et al. | Probiotics and oral health | |
| Wang et al. | Therapeutic effect of Saccharomyces boulardii combined with Bifidobacterium and on cellular immune function in children with acute diarrhea | |
| Najafi et al. | Decreased mucosal adhesion of Lactobacillus species in patients with inflammatory bowel disease | |
| CN110051702A (en) | A kind of probiotic formulation for preventing and treating hand-foot-and-mouth disease, influenza | |
| TWI598103B (en) | Composition of lactobacillus fermentum gmnl-296 and method for improving inflection symptoms of clostridium difficile | |
| CN108902981A (en) | A kind of probiotic composition and probiotics solid beverage | |
| CN111544456A (en) | Probiotic formula and application thereof | |
| Wang et al. | Effect of live Lactobacillus plantarum L2 on TNF-α-induced MCP-1 production in Caco-2 cells | |
| Dastoor et al. | Probiotics for life–Part I general health perspectives | |
| Kim et al. | Gut microbiota-mediated immunomodulatory effects of Lactobacillus rhamnosus HDB1258 cultured in the lava seawater in the colitis mouse model | |
| Gauri et al. | Probiotics as therapeutics | |
| Gomte et al. | Future Perspective and Safety Issues of Synbiotics in Different Diseases | |
| Gupta | Probiotics and human health | |
| Shivangni et al. | Probiotics: Facts and Myths |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190726 |